Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04508608
Other study ID # SciCoRIC
Secondary ID ????-?15-1151231
Status Completed
Phase
First received
Last updated
Start date September 1, 2018
Est. completion date September 1, 2021

Study information

Verified date October 2020
Source Tomsk National Research Medical Center of the Russian Academy of Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

According to single-photon emission computed tomography, the left ventricular contractile and coronary flow reserve (CFR) will be assessed in patients with ischemic cardiomyopathy. According to these data, the criteria for predicting the effectiveness of complex surgical treatment of this pathology will be evaluated.


Description:

Before surgical intervention, all patients pass routine clinical analyzes undergo coronary angiography and 2D echocardiography. Some of patients in the ICM-1 and ICM-2 groups undergo stress echocardiography with dobutamine. Coronary arteriography is performed using the Axiom Artis (Siemens; Erlangen, Germany) and transthoracic two-dimensional Doppler echocardiography (TTE) with the Acuson Sequoia 512 (Siemens; Erlangen, Germany)). Besides, all of the ICM-1 and ICM-2 groups patients undergo myocardial perfusion imaging. Standard two-day stress-rest imaging protocol is used. Adenosine at a dosage of 140 mcg/kg/min (for 4 min) is used as a pharmaceutical stress agent. ICM-1 group and Control group for GBPS undergo gated blood pool SPECT (GBPS) at rest and during increasing doses of dobutamine (5/10/15 μg/kg/min) (n = 60) ICM-2 group and Control group for CFR undergo dynamic SPECT (n = 40). This investigation is combined with routine myocardial perfusion imaging so patients are not exposed to extra stress. Than ICM patients undergo surgical treatment of ICM in different volume. All of them receive coronary bypass grafting (CABG); some patients undergo the left ventricular reconstruction and intervention on the mitral valve. In the early postoperative period (7-14 days), the ICM-1 group undergo rest GBPS and ICM-2 group undergo dynamic SPECT by two-day protocol. All patients undergo TTE too. After at least 12 month, all patients undergo TTE to assess the presence of left ventricular (LV) remodeling.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 1, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: ?) For ICM group: 1. History of myocardial infarction (MI) or revascularization (CABG or PCI); 2. > 75% stenosis of left main or proximal LAD and/ or stenosis of > 75% of =2 epicardial vessels (based on coronary angiography (CA) data); 3. LV EF <40% and increase in LV volumes according to echocardiography (ECHO) B) For GBPS Control group 1. Absence of obstructive coronary artery lesion; 2. Absence of history of MI and revascularization. C) For CFR Control group 1. Presence of obstructive coronary artery lesion; 2. Indications for coronary artery bypass grafting; Exclusion Criteria (for all groups): 1. Presence of contraindications to the stress test with inotropic stimulation; 2. Inflammatory myocardial diseases; 3. The presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research; 4. Life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Stress Gated blood pool SPECT
After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 µg / kg / min). The duration of acquisition is 300 seconds. The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)
Dynamic SPECT
The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded. At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical. The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode. The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)

Locations

Country Name City State
Russian Federation Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences Tomsk

Sponsors (1)

Lead Sponsor Collaborator
Tomsk National Research Medical Center of the Russian Academy of Sciences

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with an ongoing LV remodeling and reverse LV remodeling. Ongoing LV remodeling is meant increase of LV end-systolic volume (LVESV) or decrease of LVESV=10% according to 2D echocardiography in comparison to early postoperative period study. Reverse LV remodeling is meant decrease in LVESV >10% according to 2D echocardiography in comparison to early postoperative period study. 12 month
See also
  Status Clinical Trial Phase
Terminated NCT04066738 - Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Enrolling by invitation NCT02930265 - Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy N/A
Completed NCT01215253 - Ranolazine Implantable Cardioverter-Defibrillator Trial Phase 3
Recruiting NCT05888662 - Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT) N/A
Completed NCT03857906 - Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
Completed NCT02501811 - Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure Phase 2
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Not yet recruiting NCT01946048 - Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy Phase 1
Terminated NCT01759212 - Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure. Phase 2/Phase 3
Not yet recruiting NCT01447069 - Use of Beta-agonists in Stable Severe Congestive Heart Failure N/A
Recruiting NCT00972114 - CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT00896142 - Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation) N/A
Recruiting NCT01076660 - Left Ventricular Structural Predictors of Sudden Cardiac Death
Completed NCT00305214 - MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Completed NCT00305240 - MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Active, not recruiting NCT00962364 - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting NCT05769036 - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients N/A
Completed NCT03862339 - The SoundScar Study The SOUNDSCAR Study
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A